1. Home
  2. SMWB vs MLYS Comparison

SMWB vs MLYS Comparison

Compare SMWB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMWB
  • MLYS
  • Stock Information
  • Founded
  • SMWB 2007
  • MLYS 2019
  • Country
  • SMWB Israel
  • MLYS United States
  • Employees
  • SMWB N/A
  • MLYS N/A
  • Industry
  • SMWB Computer Software: Programming Data Processing
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SMWB Technology
  • MLYS Health Care
  • Exchange
  • SMWB Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • SMWB 1.0B
  • MLYS 893.0M
  • IPO Year
  • SMWB 2021
  • MLYS 2023
  • Fundamental
  • Price
  • SMWB $7.74
  • MLYS $13.34
  • Analyst Decision
  • SMWB Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • SMWB 8
  • MLYS 3
  • Target Price
  • SMWB $15.75
  • MLYS $33.00
  • AVG Volume (30 Days)
  • SMWB 393.9K
  • MLYS 1.1M
  • Earning Date
  • SMWB 05-06-2025
  • MLYS 05-08-2025
  • Dividend Yield
  • SMWB N/A
  • MLYS N/A
  • EPS Growth
  • SMWB N/A
  • MLYS N/A
  • EPS
  • SMWB N/A
  • MLYS N/A
  • Revenue
  • SMWB $249,913,000.00
  • MLYS N/A
  • Revenue This Year
  • SMWB $17.02
  • MLYS N/A
  • Revenue Next Year
  • SMWB $15.47
  • MLYS N/A
  • P/E Ratio
  • SMWB N/A
  • MLYS N/A
  • Revenue Growth
  • SMWB 14.63
  • MLYS N/A
  • 52 Week Low
  • SMWB $5.71
  • MLYS $8.24
  • 52 Week High
  • SMWB $17.64
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • SMWB 49.28
  • MLYS 49.34
  • Support Level
  • SMWB $6.47
  • MLYS $12.77
  • Resistance Level
  • SMWB $7.18
  • MLYS $14.16
  • Average True Range (ATR)
  • SMWB 0.45
  • MLYS 1.13
  • MACD
  • SMWB 0.20
  • MLYS -0.04
  • Stochastic Oscillator
  • SMWB 92.01
  • MLYS 66.06

About SMWB Similarweb Ltd.

Similarweb Ltd provides a platform for digital intelligence, delivering a trusted, comprehensive, and detailed view of the digital world that empowers customers to accelerate their growth and become more competitive in the markets. Its proprietary technology analyzes billions of digital interactions and transactions every day from millions of websites and apps and turns these digital signals into actionable insights. The company generates revenues mainly from SaaS subscriptions, which comprise subscription fees from customers utilizing cloud-based digital intelligence solutions and other subscription-based solutions. Geographically, the majority of its revenue is derived from the United States and rest from Israel, United Kingdom, Europe, Asia Pacific and other regions.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: